Trading Signals: CLVS Stock Price Prediction and Forecast (Wed. Nov. 16, 2011 - Fri. Aug. 6, 2021)(Clovis Oncology Inc. )
| CLVS latest price $32.5800 (0.43%) ($31.6200 - $33.1900) on Tue. Oct. 11, 2016. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 5.99% (three month average) | RSI | 46 | Latest Price | $32.5800(0.43%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | CLVS declines -1.3% a day on average for past five trading days. | Weekly Trend | CLVS declines -5.1% a week on average for past two weeks. | Market Behavior | Broad based sell-off for large cap. Broad based sell-off for small cap. | Correlated ETFs | Broad market will support CLVS advance at 0% a week (0% probability) XBI(23%) IBB(20%) ARKG(17%) ARKK(14%) IWO(13%) | Factors Impacting CLVS price | CLVS will decline at least -2.995% in a week (0% probabilities). VIXM(-9%) IPO(-6%) SHY(-5%) GDXJ(-5%) TLT(-4%) | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -2.995% (StdDev 5.99%) | Hourly BBV | 0 () | Intraday Trend | 1.6% | | | |
|
Resistance Level | $34.43 | 5 Day Moving Average | $33.5(-2.75%) | 10 Day Moving Average | $34.38(-5.24%) | 20 Day Moving Average | $34.43(-5.37%) | To recent high | -15.1% | To recent low | 137.6% | Market Cap | $2.873b | | | | Clovis Oncology, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of cancer treatments. Its marketed product Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase (PARP), is offered for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer. The company was founded by Andrew R. Allen, Gillian C. Ivers-Read, Patrick J. Mahaffy, and Erle T. Mast on April 20, 2009 and is headquartered in Boulder, CO. |